Hypertension Detection and Follow-up Program Mainstream, Final, and Associated Publications


8. The Hypertension Detection and Follow-up Program. Langford HG, Payne G, Remington RD, Stamler J. In Epidemiology and Control of Hypertension, O. Paul (editor), Stratton Intercontinental Medical Book Corporation, New York, 1975; pp:663-672. (Paper 1A)


25. Recent status of detection, treatment and
control of hypertension in the community. Wassertheil-Smoller S, Apostolidies A, Miller M, Oberman A, Thom T, on behalf of the Hypertension Detection and Follow-up Program. *Journal of Community Health* 1979; 5:82-93. (Paper 20)

26. Five-year findings of the HDFP. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. HDFP Cooperative Group. *JAMA* 1979; 242:2562-2571. (Final Paper 1)

27. Five-year findings of the HDFP. II. Mortality by race-sex and age. HDFP Cooperative Group. *JAMA* 1979; 242:2572-2577. (Final Paper 2)


33. Application of survival analysis techniques to evaluation of factors affecting compliance in a clinical trial of hypertension control. Smith EO, Hardy RJ, Cutter GR, Curb JD, Hawkins CM. *Controlled Clinical Trials* 1980; 1:59-69. (Paper 54A)


35. A two-compartment regression model applied to compliance in a hypertension treatment program. Smith EO, Hardy RJ, Cutter GR. *J Chron Dis* 1980; 33:645-651. (Paper 54C)


41. Reserpine and breast cancer in the HDFP. Curb JD, Hardy RJ, Labarthe DR, Borhani NO, Taylor JO. *Hypertension* 1982; 4:307-311. (Paper 56)


43. Clinic attendance in the HDFP. Smith EO, Curb JD, Hardy RJ, Hawkins CM, Tyroler HA. *Hypertension* 1982; 4:710-715. (Paper 54)


49. Predictive values of routine blood pressure


66. Five-year findings of the HDFP: Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. HDFP Cooperative Group. *Hypertension* 1985; 7:105-112. (Final Paper 4)


73. Cardiovascular morbidity and mortality in


81. Implications of the HDFP. The HDFP Cooperative Group. *Progress in Cardiovascular Diseases* 1986;29:3-10. (Five-Year Monograph)

82. HDFP design, methods, and baseline characteristics and blood pressure response of the study participants. Davis BR, Ford CE, Remington RD, Stampler R, Hawkins CM. *Progress Cardiovascular Diseases* 1986;29:11-28. (Five-Year Monograph)

83. All-cause mortality in the HDFP: Findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Langford HG, Stampler J, Wassertheil-Smoller S, Prineas RJ. *Progress Cardiovascular Diseases* 1986; 29:29-54. (Five-Year Monograph)

84. Incidence of coronary heart disease and left ventricular hypertrophy in the HDFP. Borhani NO, Blaufox MD, Oberman A, Polk BF. *Prog Cardiovas Dis* 1986; 29:55-62. (Five-Year Monograph)


86. Adverse effects of antihypertensive medications in the HDFP. Curb JD, Maxwell MH, Schneider KA, Taylor JO, Shulman NB. *Prog Cardiovas Dis* 1986; 29:73-88. (Five-Year Monograph)


92. Education level and five-year all cause mortality in the HDFP. HDFP Cooperative Group. *Hypertension* 1987; 9:641-646. (Final Paper 7)

93. Failure to reduce cholesterol as explanation for the limited efficacy of antihypertensive treatment in the reduction of CHD. Evidence from the HDFP. Schneider KA, Heyden S, Ford CE. *Nephron* 1987; 47(Suppl 1):104-107. (Paper 107A)


95. Mortality at eight years for Hypertension Detection and Follow-up Program participants. Langford HG. In *Mild Hypertension: From Drug Trials to Practice*. T. Strasser and D. Ganten, editors. Raven


100. Mortality findings beyond five years in the Hypertension Detection and Follow-up Program. Daugherty SA. *J Hypertension* 1988; 6(Suppl 4):S597-S601. (PTS Final Paper 1B)


Letters


Related Publications

Phase I, Local Center Papers


3. Recent trends in hypertension control. Ward

5. **Implications of findings in the HDFP.** Saunders E. *Urban Health* 1981; May:26-27, 40.


HDFP Presentations and Abstracts

The name of the presenter has been underlined when multiple authors are listed and only one made the presentation.

1. Remington RD, on behalf of the HDFP. The Hypertension Detection and Follow-up Program. (Presented at the INVITED SESSION AT THE INTERNATIONAL HYPERTENSION SYMPOSIUM. Chicago, Illinois, September 1974.)

2. Langford HG, on behalf of the HDFP. The Hypertension Detection and Follow-up Program. (Presented at the INVITED SESSION AT THE INTERNATIONAL HYPERTENSION SYMPOSIUM. Chicago, Illinois, September 1974.)

3. Oberman A, on behalf of the HDFP.

4. Blaufox MD, on behalf of the HDFP.

5. Langford HG, on behalf of the HDFP.

6. Wassertheil-Smoller S, on behalf of the HDFP.

7. McDill MS, Heymsfield S, Kraus JF, Lee ES, on behalf of the HDFP.

8. Taylor JO, on behalf of the HDFP.


11. Borhani NO, on behalf of the HDFP. The Hypertension Detection and Follow-up Program. (Presented at the AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC SESSIONS. New York, February 1977.)

12. Polk BF, on behalf of the HDFP. Mild hypertensives in the HDFP. (Presented at the AMERICAN COLLEGE OF CARDIOLOGY SYMPOSIUM ON CLINICAL TRIALS. Las Vegas, Nevada, March 1977.)

13. Payne GH, on behalf of the HDFP.

14. Heyden S, on behalf of the HDFP.

15. Prineas R, on behalf of the HDFP.


17. Borhani NO, on behalf of the HDFP.

18. Sigourney L, on behalf of the HDFP.

19. Polk BF, on behalf of the HDFP.
20. Smith EO. Life table analysis of time until drop-out in the HDFP. (Presented at the 4TH ANNUAL MEETING OF PERSONNEL INVOLVED IN COORDINATING COLLABORATIVE CLINICAL TRIALS. Chapel Hill, North Carolina, May 1977.)

21. Ford CE. Monitoring clinical trial study data acquisition by means of an interactive information management system. (Presented at the 4TH ANNUAL MEETING OF PERSONNEL INVOLVED IN COORDINATING COLLABORATIVE CLINICAL TRIALS. Chapel Hill, North Carolina, May 1977.)

22. Langford HG, on behalf of the HDFP. The Hypertension Detection and Follow-up Program. (Presented at a WHO INTERNATIONAL SYMPOSIUM ON PROPHYLACTIC APPROACH TO HYPERTENSIVE DISEASE. Izumo, Japan, September 1978.)


27. Blaufox MD, Langford HG, Ford CE, on behalf of the HDFP. End-organ damage in hypertension and medication requirements for control of blood pressure. (Presented at the 52ND SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Anaheim, California, November 1979.) Abstract: Circulation 1979; 60(Suppl II):II-68.


29. Maxwell M, on behalf of the HDFP. Final results of the HDFP. (Presented at 7TH SCIENTIFIC MEETING OF THE INTERNATIONAL SOCIETY OF HYPERTENSION. New Orleans, Louisiana, May 1980.)


32. Borhani NO, Langford HG, and non-HDFP Investigators. (PANEL PRESENTATION IN A SATELLITE PROGRAM: Implications of the Australian Study and HDFP. September 1980.)


37. Molteni A, on behalf of the HDFP. The effect of hypertension on serum indicators of renal function. (Presented at the ASSOCIATION OF CLINICAL SCIENTIST MEETING. Chicago, Illinois, November 1980.)


40. Borhani NO, on behalf of the HDFP. Reduction in stroke incidence among persons with high blood pressure. (Presented at AMERICAN EPIDEMIOLOGICAL SOCIETY. Chicago, Illinois, April 1981.)


42. Labarthe D. The relationship between serum cholesterol and cancer incidence in the population of the HDFP. (Presented at the WORKSHOP ON CHOLESTEROL AND NONCARDIOVASCULAR DISEASE MORTALITY. Bethesda, Maryland, May 1981.)


49. Langford HG, Curb JD, Blaufox D, Borhani NO, Chakrin A, on behalf of the HDFP. Thiazide produced uric acid elevations do not cause renal damage. (Presented at the SOUTHERN SOCIETY FOR CLINICAL INVESTIGATION MEETING. New Orleans, Louisiana, January 1982.) Abstract: Clinical Research 1981; 29:865A.

50. Langford HG, on behalf of the HDFP. Further findings of HDFP. (Presented at INTERNATIONAL SOCIETY OF HYPERTENSION MEETING. Mexico City, February 1982.)


54. Taylor JO, on behalf of the HDFP. Mortality in the HDFP by race, sex, and blood pressure level—a further analysis. (Presented at the 22ND ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. San Antonio, Texas, March 1982.) Abstract: CVD Epidemiology Newsletter 1982; 32:xx.


56. Langford HG, on behalf of the HDFP. Prognostic importance and effect of Stepped Care regimen on indices of coronary artery and myocardial disease. (Presented at the SOUTHERN SOCIETY FOR CLINICAL INVESTIGATION MEETING. New Orleans, Louisiana, January 1982.) Abstract: Clinical Research 1982; 30:547A.

57. Curb JD, Langford HG, Blaufox D, Borhani NO, Chakrin A, on behalf of the HDFP. Thiazide
produced uric acid elevations do not cause renal damage.  
Abstract: Clinical Research 1982; 30:509A.

58. Borhani NO, on behalf of the HDFP.  
Beneficial effect of the HDFP Stepped Care regimen on indices of coronary artery and myocardial disease.  
(Presented at the AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC SESSION.  Atlanta, Georgia, April 1982.)  

59. Taylor JO, on behalf of the HDFP.  
The Hypertension Detection and Follow-up Program: a systematic approach that works.  
Presented at ASSOCIATION OF TEACHERS OF PREVENTIVE MEDICINE.  Bethesda Maryland, April 1982.

60. Curb JD, Babcock C, Pressel S, Tung B, Hawkins CM.  
Nosological coding of cause of death in a clinical trial.  
(Presented at the 3RD ANNUAL MEETING OF THE SOCIETY FOR CLINICAL TRIALS.  Pittsburgh, Pennsylvania, May 1982.)  
Abstract: Controlled Clinical Trials 1982; 3:141.

61. Polk BF, on behalf of the HDFP.  
Effect of antihypertensive medication on left ventricular hypertrophy.  
(Presented at 15TH MEETING OF THE SOCIETY FOR EPIDEMIOLOGIC RESEARCH.  Cincinnati, Ohio, June 1982.)  

62. Taylor JO, on behalf of the HDFP.  
Mortality in the HDFP by race, sex, and blood pressure level—a further analysis.  
(Presented at 15TH MEETING OF THE SOCIETY FOR EPIDEMIOLOGIC RESEARCH.  Cincinnati, Ohio, June 1982.)  

63. Borhani NO.  
Beneficial effect of the HDFP Stepped Care regimen on indices of coronary artery and myocardial disease.  
(Presented at the 15TH MEETING OF THE SOCIETY FOR EPIDEMIOLOGIC RESEARCH.  Cincinnati, Ohio, June 1982.)  

64. Curb JD, Schnaper H, Williams W, Entwisle G, Kass E, Borhani NO, on behalf of the HDFP.  
Detection and treatment of hypertension in the elderly.  
(Presented at the 15TH MEETING OF THE SOCIETY FOR EPIDEMIOLOGIC RESEARCH.  Cincinnati, Ohio, June 1982.)  

65. Stamler J.  
Five-year morbidity and mortality in the HDFP.  
(Presented at IX WORLD CONGRESS OF CARDIOLOGY.  Moscow, USSR, June 1982.)

66. Tyrolder HA.  
Race, education, and five-year mortality in HDFP stratum I Referred Cases.  
(Presented in an Invited Session at the 3RD WHO/ISH CONFERENCE ON MILD HYPERTENSION: RECENT ADVANCES.  Geneva, Switzerland, September 1982.)

67. Langford HG.  
Further analyses of the HDFP.  
(Presented in an Invited Session at WHO MEETING.  Geneva, Switzerland, September 1982.)

68. Berman R.  
Mortality reduction among persons with "mild" hypertension.  
(Presented at 5TH SCIENTIFIC MEETING OF THE WORKING GROUP ON EPIDEMIOLOGY AND PREVENTION OF THE EUROPEAN SOCIETY OF CARDIOLOGY.  Barcelona, Spain, September 1982.)

69. Blaufox MD.  
Reduction in hypertension mortality through Stepped Care in the HDFP, and reduction in cardiovascular complications of hypertension in the HDFP.  
(Presented at the INTERNATIONAL SYMPOSIUM ON HYPERTENSION CONTROL IN THE COMMUNITY.  Tel Aviv, Israel, October 1982.)

70. HDFP Investigators.  

71. Curb JD, Borhani NO, Blaszkowski T, Fotiu S, Zimbaldi N, on behalf of the HDFP.  
Adverse reactions to antihypertensive drugs in the HDFP.  
(Presented at the 55TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION.  Dallas, Texas, November 1982.)  

72. Daugherty SA, Curb JD, Pressel S, Taylor JO, Apostolides A, Newman B, Detels R, on behalf of the HDFP.  
The relationship of blood pressure to 5-year mortality in a community-based population.  
(Presented at the 55TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION.  Dallas, Texas, November 1982.)  

73. Oberman A, Entwisle G, Langford H, Borhani N, Tung B, on behalf of the HDFP.  
Assessing racial differences in angina pectoris among hypertensives.  
(Presented at the 55TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION.  Dallas, Texas, November 1982.)  

74. Hardy RJ, Hawkins CM, on behalf of the HDFP.  
The impact of selected indices of antihypertensive treatment on all-cause mortality.  
(Presented at the 55TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION.  Dallas, Texas, November 1982.)  

75. Langford HG, on behalf of the HDFP.  
Blood pressure and CHD indices and mortality in HDFP.  
(Presented in an Invited Session at the 23RD ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY: SYMPOSIUM ON CORONARY HEART DISEASE IN BLACK POPULATIONS.  San Diego, California, March 1983.)

76. Hardy RJ, Hawkins CM, on behalf of the HDFP.  
The impact of selected indices of antihypertensive treatment on all-cause


79. Schneider KA, on behalf of the HDFP. Mortality reduction among persons with "mild" hypertension. (Presented at NATIONAL CONFERENCE ON HIGH BLOOD PRESSURE CONTROL. Washington D.C., April 1983.)

80. Williams WR, Borhani NO, Schnaper HW, Schneider KA, Slotkoff L, on behalf of the HDFP. The relationship between diuretics and serum cholesterol in HDFP participants. (Presented at NATIONAL CONFERENCE ON HIGH BLOOD PRESSURE CONTROL. Washington D.C., April 1983.)

81. Curb JD, Hardy RJ, Hawkins CM, on behalf of the HDFP. The impact of selected indices of antihypertensive treatment on all-cause mortality. (Presented at NATIONAL CONFERENCE ON HIGH BLOOD PRESSURE CONTROL. Washington D.C., April 1983.)

82. Curb JD, Borhani NO, Blaszkowski T, Fotiu S, Zimbaldi N, on behalf of the HDFP. Adverse reactions to antihypertensive drugs in the HDFP. (Presented at NATIONAL CONFERENCE ON HIGH BLOOD PRESSURE CONTROL. Washington D.C., April 1983.)

83. Schneider KA, on behalf of the HDFP. The relationship between diuretics and serum cholesterol: The HDFP experience. (Presented at the WORKSHOP ON THE ROLE OF DIETARY MANAGEMENT IN THE REDUCTION OR REVERSAL OF BLOOD LIPID ELEVATIONS INDUCED BY ANTIHYPERTENSIVE MEDICATIONS. Bethesda, Maryland, April 1983.)


87. Polk BF. Evidence for an association between first birth order and hypertension. (Presented at the XIII WORLD CONGRESS OF THE INTERNATIONAL UNION OF ANGIOLOGY. Rochester, Minnesota, September 1983.)

88. Ellefson RD, on behalf of the HDFP. The relationship between diuretics and serum cholesterol in HDFP participants. (Presented at the 56TH SCIENTIFIC SESSIONS OF THE AMERICAN FEDERATION FOR CLINICAL RESEARCH. Cambridge, Massachusetts, October 1983.)

89. Taylor JO, on behalf of the HDFP. Prevention and reversal of left ventricular hypertrophy and cardiomegaly with antihypertensive drug therapy. (Presented at the EASTERN SECTION MEETING OF THE AMERICAN FEDERATION FOR CLINICAL RESEARCH. Anaheim, California, November 1983.)

90. Taylor JO, on behalf of the HDFP. Findings of the HDFP. (Presented at the EASTERN SECTION MEETING OF THE AMERICAN FEDERATION FOR CLINICAL RESEARCH. Cambridge, Massachusetts, October 1983.)


93. Borhani NO, on behalf of the HDFP. Prevention and reversal of left ventricular hypertrophy and cardiomegaly with mortality. (Presented at the 23RD ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. San Diego, California, March 1983.) Abstract: CVD Epidemiology Newsletter 1983; 33:48.
antihypertensive drug therapy. (Presented at the WESTERN SECTION MEETING OF THE AMERICAN FEDERATION FOR CLINICAL RESEARCH. Carmel, California, February, 1984.)

94. Borhani NO, on behalf of the HDFP. Effect of Stepped Care treatment on the incidence of myocardial infarction and angina pectoris. (Presented at the WESTERN SECTION MEETING OF THE AMERICAN FEDERATION FOR CLINICAL RESEARCH. Carmel, California, February, 1984.)

95. Maxwell MH, Ford CE, on behalf of the HDFP. Cardiovascular morbidity and mortality in HDFP patients 50-69 years old at entry. (Presented at a SATELLITE SYMPOSIUM ON CARDIOVASCULAR MORBIDITY AND LARGE ARTERIES IN HYPERTENSION. Paris, France, June 1984.)

96. Stamler J, on behalf of the HDFP. Mortality findings for Stepped Care and Referred Care participants in the HDFP, stratified by other risk factors. (Presented at the 57TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Miami Beach, Florida, November 1984.) Abstract: Circulation 1984; 70(Suppl III):??.

97. Langford HG, Ford CE, Blaufox MD, on behalf of the HDFP. Is hypertension worse in blacks? Comparison of creatinine levels at equal blood pressures; effect of potassium. (Presented at the 17TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF NEPHROLOGY. New Orleans, Louisiana, January 1985.)

98. Stamler R, on behalf of the HDFP. Education level, hypertension treatment, and 5-year mortality in the HDFP. (Presented at the 25TH ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. Tucson, Arizona, March 1985.) Abstract: Circulation 1985; 71:413A.


105. Ford CE, Langford HG, Palmer MJ. Recruitment in the Hypertension Detection and Follow-up Program. Presented at the NHLBI WORKSHOP ON THE RECRUITMENT EXPERIENCE IN NHLBI-SUPPORTED CLINICAL TRIALS. Bethesda, Maryland, April 1986. Abstract: Controlled Clinical Trials 1987; 8(Suppl):??.


108. Borhani NO, on behalf of the HDFP. Eight-year follow-up of participants in the HDFP: persistence of reduction in blood pressure and mortality in a treated hypertension population. (Presented at the 11TH CONGRESS OF THE INTERNATIONAL SOCIETY OF HYPERTENSION. Heidelberg, Federal Republic of Germany, September 1986.)

109. Schneider KA, Ford CE, Davis BR, Heyden S, Tyroer HA. Cholesterol and coronary heart disease in HDFP hypertensive participants. (Presented at the 27TH ANNUAL CONFERENCE ON...
CARDIOVASCULAR DISEASE EPIDEMIOLOGY. Charleston, South Carolina, March 1987.) Abstract: CVD Epidemiology Newsletter 1987; 41:76.


111. Daugherty SA, on behalf of the HDFP. Mortality findings beyond five years in the HDFP. (Presented at the 12TH SCIENTIFIC MEETING OF THE INTERNATIONAL SOCIETY OF HYPERTENSION. Kyoto, Japan, May 1988.) Published: J Hypertension 1988; 6(Suppl 4):S597-S601, as part of the meeting proceedings.


113. HDFP Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. Abstract: Modern Medicine Abstracts 1988; ??.

114. Moorman PG, Ford CE, Tyroler HA. Educational level and all-cause mortality in the HDFP trial and Post-Trial Surveillance Study (PTSS). (Presented at the 13TH SCIENTIFIC MEETING OF THE INTERNATIONAL SOCIETY OF HYPERTENSION, June 1990, in Montreal, Canada.)

